SUSVIMO
As listed in the register: SUSVIMO 100 MG/ML SOLUCION INYECTABLE
100 mg/ml · solución inyectable
- Prescription only
- Eyes and ears
- Active substance
- Ranibizumab
- Used in
- Eyes and ears
- Made by
- Roche Registration Gmbh
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
Mediclarum has not yet retrieved and stored the official label for this product, so none of its text is shown here. Open the official leaflet
How it works
From the US prescribing label for the same active substance (LUCENTIS). It describes the substance, not this exact product.
Ranibizumab binds to the receptor binding site of active forms of VEGF-A, including the biologically active, cleaved form of this molecule, VEGF 110.
VEGF-A has been shown to cause neovascularization and leakage in models of ocular angiogenesis and vascular occlusion and is thought to contribute to pathophysiology of neovascular AMD, mCNV, DR, DME and macular edema following RVO.
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2025-11-21
Safety of the active substance
From the US prescribing label for the same active substance (LUCENTIS). It describes the substance, not this exact product.
- Ocular or periocular infections ( 4.1 ) Hypersensitivity ( 4.2 ) 4.1 Ocular or Periocular Infections LUCENTIS is contraindicated in patients with ocular or periocular infections. 4.2 Hypersensitivity LUCENTIS is contraindicated in patients with known hypersensitivity to ranibizumab or any of the excipients in LUCENTIS.
- Hypersensitivity reactions may manifest as severe intraocular inflammation.
Quoted from the US prescribing label for the same active substance. Your own pack’s leaflet is the authority for your product. DailyMed
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
European UnionNo exact match for this strength and form
FranceNo exact match for this strength and form
CanadaNo exact match for this strength and form
NetherlandsNo exact match for this strength and form
SwitzerlandNo exact match for this strength and form
Details
| Made by | Roche Registration Gmbh |
|---|---|
| Active substance | Ranibizumab |
| Used in | Eyes and ears |
| Strength | 100 mg/ml |
| Form | solución inyectable |
| Classification | S01LA04 · Eyes and ears |
| Route | vía intravítrea |
| Marketed | No — authorised but not currently marketed, according to the register |
| Additional monitoring ▼ | Yes — under additional monitoring (black triangle). Report suspected side effects. |
| Driving | The regulator flags that this medicine can affect the ability to drive. |
| Name in the register | SUSVIMO 100 MG/ML SOLUCION INYECTABLE |
| Nº Registro | 1262058001 |
Source: CIMA — Centro de Información online de Medicamentos · 2026-09-30 · not reviewed by a clinician
Fuente: Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), CIMA. Reuse terms: Aviso legal AEMPS.
Same active substance
These contain the same substance. That does not mean one can replace another — ask a pharmacist.